Indication
Stocrin is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children three years of age and older. Stocrin has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease-inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing Stocrin.
In other countries
The same active substances on other registers, the same brand first.
- StocrinBrazil · Organon Farmacêutica Ltda.Same brand
- STOCRIN 600 mgRomania · 600mg · compr. film. · Merck Sharp & Dohme B.V.Same brand
- STOCRIN 600mgRomania · 600mg · compr. film. · Merck Sharp & Dohme LTDSame brand
- EfavirenzBrazil · Fundação Oswaldo CruzSame form
- EvirBrazil · Cristália Produtos Químicos Farmacêuticos Ltda.Same form